Healx vs Lunit

Lunit has a disclosed valuation of $829M, while Healx's valuation is not publicly available, making a direct size comparison difficult. Lunit employs 300 people.

Lunit has raised more in total funding at $150M, compared to Healx's $47M — a gap of $103M. Combined, the two companies have completed 4 known funding rounds.

Lunit holds the higher Awaira Score at 63/100, compared to Healx's 55/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 8-point gap that reflects meaningful differences in scale or traction.

Healx was founded by Tim Guilliams in 2014. Lunit was founded by Brandon Suh in 2013. Visit each company's profile on Awaira for a full founder biography.

Healx: Healx uses AI to identify and develop treatments for rare diseases, applying graph neural networks and multi-omics data analysis to repurpose existing approved drugs for new orphan disease indications. The Cambridge-based company focuses exclusively on rare diseases, where the small patient populations and limited existing literature make traditional drug discovery economically unviable without computational approaches that can extract signal from sparse data.\n\nThe company raised a $47 million Series B led by Balderton Capital and includes strategic investors from the rare disease patient advocacy community. Healx has assembled a pipeline of repurposing candidates for conditions including Fragile X syndrome, tuberous sclerosis complex, and other rare neurodevelopmental disorders, with several candidates advancing into clinical studies. The company partners with patient advocacy groups to access natural history data and patient registries that inform its disease models.\n\nHealx operates in a rare disease AI market that is less crowded than oncology-focused drug discovery AI but equally challenging due to regulatory complexity and small trial populations. The company competes with Healios, BenevolentAI, and specialist rare disease biotechs that are increasingly adopting computational methods. Its exclusive focus on rare diseases and its community partnerships represent a defensible niche that larger generalist AI drug discovery platforms have not prioritised. Lunit: Lunit is a South Korean AI healthcare company founded in 2013 that specializes in diagnostic imaging analysis using artificial intelligence. The company develops machine learning algorithms designed to assist radiologists in detecting abnormalities across medical imaging modalities, particularly in chest radiography, breast cancer screening, and CT scans. Lunit's core platform uses deep learning to analyze medical images and provide clinical decision support, aiming to improve diagnostic accuracy and efficiency in healthcare settings. The company's primary products include Lunit INSIGHT, a software solution that integrates with existing hospital infrastructure and picture archiving systems. Lunit has established a presence across Asia, Europe, and other regions, with its technology deployed in hospitals and diagnostic centers. The company went public on the Korean stock exchange, achieving a valuation of $0.8 billion. With $150 million in total funding raised through various rounds before its public listing, Lunit operates in a competitive segment alongside companies like Zebra Medical Vision, Arterys, and various regional competitors. The company faces competition from both specialized AI diagnostic firms and larger healthcare technology providers developing similar capabilities. Lunit's growth trajectory reflects increasing adoption of AI in medical imaging across Asia-Pacific markets, where regulatory pathways and healthcare infrastructure continue to evolve to accommodate such technologies. Lunit is among the few AI medical imaging companies to achieve public market status, particularly from South Korea, reflecting regional strength in healthcare technology innovation.

Lunit was founded first in 2013, giving it 1 year of additional market experience. Healx was founded later in 2014. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Healx has approximately 1-50 employees, while Lunit has approximately 300. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Healx and Lunit are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.